RxDoctor Payments Data

Jacqueline Sebastian, NP

Nurse Practitioner · Cary, NCNPI 1386752228

Payments from drug & device makers

$2,476in general payments, 2019–2025

Across 106 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$459
  • Amgen$450
  • AstraZeneca$204
  • Ardelyx, Inc.$175
  • Nxstage Medical, Inc.$170
  • Mallinckrodt Hospital Products Inc.$145
  • plus $873 from 14 others

What the payments were for

  • Food & beverage$2,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,476 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,800
Medicare patients
89
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide79$172,543
AuryxiaFerric Citrate11$32,444
JardianceEmpagliflozin26$21,930
KerendiaFinerenone16$18,132
BrilintaTicagrelor12$5,697
Sevelamer Carbonate18$1,278
Midodrine Hcl12$890
Bumetanide23$720
Lidocaine-PrilocaineLidocaine/Prilocaine17$525
Gabapentin39$457
Albuterol Sulfate HfaAlbuterol Sulfate18$420
Mirtazapine16$396
Amlodipine Besylate32$308
Losartan Potassium34$255
Sertraline Hcl29$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$459$172,54379 claims
Akebia Therapeutics IncAuryxia$19$32,44411 claims
Boehringer IngelheimJardiance$117$21,93026 claims
BayerKerendia$131$18,13216 claims
AstraZenecaBrilinta$204$5,69712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →